贾 力
来源:未知 作者:admin 更新时间:2019-05-06


Name: Lee Jia
Business Address: Sunlight Building, 6FL; Science Park, Xueyuan Road, University Town; Cancer Metastasis Alert and Prevention Center, Fuzhou University, Fuzhou, Fujian 350116, China;
Business Email and Phone: pharmlink@gmail.com; cmapcjia1234@163.com Phone: 011-1515-963-0201 (China);
1994-1996 Post-Doctoral Fellow, Department of Medicine, Divisions of Respiratory & Cardiovascular Medicine, Duke University Medical Center, Durham, NC, USA
1990-1994 Ph.D. (Pharmacology), State University of New York, NY, USA: Mentor Dr. Robert F. Furchgott, the 1998 Nobel Laureate.
1984-1987 M.S. (Pharmaceutical Science), China Pharmaceutical University, China
1978-1982 B.S.  (Pharmacy), Fudan University, College of Pharmacy, China.
01/2012-present Distinguished Professor, “The China Recruitment Program of Global Experts” (1000-talent plan); Founding Director, Cancer Metastasis Prevention & Alert Center, Fuzhou University, China.
09/2014-present Director, Biopharmaceutical Photocatalysis of State Key Laboratory of Photocatalysis on Energy and Environment, Fuzhou University
12/2015-present Director, Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy (Fuzhou University)
4/2005-4/2012 Senior Pharmacologist; Senior Project Officer (Permanent Tenure, GS14/Step 9), Toxicology and Pharmacology Branch, Developmental Therapeutics Program (DTP), Division of Cancer Treatment & Diagnosis, National Cancer Institute/ NIH; Rockville, MD.

4/2002-2005 Senior Pharmacologist; Project Officer (Conditional Tenure, GS14/
Step 6), Developmental Therapeutics Program (DTP), Division of Cancer Treatment & Diagnosis, National Cancer Institute/ NIH; Rockville, MD.
2008-Present Visiting Professor, Chinese Academy of Science Key Laboratory for Biomedical Effects of Nanomaterials and Nano-safety, Beijing, China.  
2/2000-3/2002 Associate Director, Department of Translational Research; Head, PK/PD Laboratory. Institute for Drug Development/ Cancer Therapy & Research Center, San Antonio, TX;
5/2000-3/2002 Associate Member (equivalent to Associate Professor), San Antonio Cancer Institute, San Antonio, TX.
1998-1999 Group Leader and Member of IACUC (Institutional Animal Care and Use Committee), La Jolla Pharmaceutical Company, San Diego, CA.
1996-1998 Senior Researcher, Dept. of Medicine, Uni. California San Diego, CA.   
            Visiting Scholar, Chinese Academy of Medical Sciences, Beijing, China.
1994-1996 Post-doctor, NitroMed Inc. / Department of Medicine, Divisions of Respiratory & Cardiovascular Medicine, Duke University Medical Center, Durham, NC.
1990-1994 PhD. Research supervised by Dr. Robert F. Furchgott, the 1998 Nobel Laureate, SUNY, NY.
1987-1989  Project Leader, Clinical Pharmacy and Pharmacology, East Hospital, China

· 2015 Most Cited Chinese Researchers selected by Scopus/ Elsevier Research Intelligence 
· 2014 Most Cited Chinese Researchers selected by Scopus/ Elsevier Research Intelligence 
· Committee of Botanic Drug Metabolism and Clinical Monitoring Society/ World Federation of Chinese Medicine Societies 世界中医药学联合会/ 植物药代谢与临床监测专业委员会委员 (2016-present)
· Commission Member of Free Radical Biology and Medicine, The Biophysical Society of China (中國生物物理學會自由基生物學與自由基醫學專業委員會, 2014-president) 
· “Honorable Fuzhou Citizen” (2014) awarded by the Fuzhou City Standing Committee for his outstanding contributions to the promotion of the development and expansion of international exchanges and cooperation to make the economic and social prosper of Fuzhou   
· The China Recruitment Program of Global Experts Award (2011)
· The Fujian Science & Technology Innovation Leadership Award (2011).
· Member, American Association of Pharmaceutical Scientists (AAPS, 135447)
· Committee, Fujian Pharmacological Society, China (2012-present)
· Vice-Chair, Chair-elect, Chair and Past Chair (2009-2013), AAPS Drug Design & Discovery Section
· 2012 AAPS Program Coordination Committee, Award Committee 
· 2011 AAPS annual meeting programming committee
· Chair-elected (2007-2009), and Chair (2009-2010), AAPS CRO Focus Group (600+ members) 
· AAPS Nanotechnology Focus Group Steering Committee
· AAPS Fellow (2011) 
· Member, American Association for Cancer Research (AACR, 75164)
· Member, American Society of Gene & Cell Therapy (ASGCT; 2016- present; Member ID25579; account/code: LeeJia541123)
· Member, American Heart Association (1997-2000)
· Executive Board Member, State University of New York Alumni Association (2004-2010)
· 2004 National Cancer Institute Merit Awards
· 1998 American Heart Society Travelship Award 
· Yangtze River (Changjiang) Scholar Distinguished Professor (1999);
· First-class Army Science and Technology Progress Award: S-nitrosohemoglobin,1997
· Vice Chair, Graduate Student Association, China Pharmaceutical University (1985-1987)  
Organize review processes for submitted manuscripts, including identifying and inviting qualified reviewers, analyzing reviewers’ critiques, comments, and overall scores to make final fair justifications, setting criteria for acceptance, rejection, and revision.    
1. Associate Editor, Current Drug Metabolism (2005-present);
2. Editorial Advisory Board Member, Current NanoSciences (2005-present);
3. International Editorial Advisory Board, Therapeutic Delivery (2010-present);
4. Editorial Board Member, Pharmaceutica Analytica Acta (2010-present)
5. Editorial Board Member, Pharmaceutical Regulatory Affairs (OMICS Publishing Group; 2011-pesent)
6. Editorial Board Member, International J. Tumor Therapy; Scientific & Academic Publishing (2011-Present)
7. Associate Editor, Drug Metabolism Letter (2007-present);
8. Editorial Advisory Board Member, Current Bioactive Compounds (2007-present);
9. Editorial Board Member, The Open Drug Metabolism Journal (2008-present);
10. Editorial Advisory Board Member, The Open Drug Delivery Journal (2008-present);
11. 《药物分析杂志》特邀编委(Editor, Pharmaceutical analysis Journal)(2012年--)
12. 《贵阳医学院学报》特邀编委(Editor, Guiyang Medicinal College J.)(2013年--)
13. Advisor to the Science and Technology Group Publishers (2008-present);
Invited  or ad hoc Reviewers for the Following 40 Journals:
1. Cell Biology & Toxicology;
2. J. Pharm. Sci;
3. Brain Research;
4. Biochem Pharmacol;
5. Letters in Drug Design & Discovery;
6. Rapid Communications in Mass Spectrometry;
7. Biopharmaceutics & Drug Disposition;
8. J. Pharm. BioMed. Anal;
9. Clinica Chimica Acta;
10. NeuroScience Letters;
11. J. Pharmacol. Exp. Ther;
12. Molecular Pharmacology;
13. Anti-Cancer Agents in Medicinal Chemistry; 
14. Current Drug Metabolism; 
15. Bioorganic & Medicinal Chemistry Letters;
16. Biomedical Chromatography;
17. J. Chromatography;
18. Planta Medica;
19. Xenobiotics;
20. Molecular Pharmaceutics;
21. Acta Pharmacol Sin.;
22. Drug Metabolism Letter;
23. Curr. NanoScience;
24. Arch Pharmacol.;
25. Drug Metabolism and Disposition (ASPET);
26. Toxicology Letter;
27. Chinese Medicine
28. Current HIV Research
29. J. NanoSci. NanoTech.
30. Therapeutic Delivery
31. Journal of Medicinal Plant Research
32. Drug Discovery Today
33. Biomaterials (IF8.557)
34. Current Medicinal Chemistry
35. Toxicological Sciences
36. Journal of Acquired Immune Deficiency Syndromes (JAIDS)
37. The AAPS J
38. Oncotarget (IF6.63)
39. Science Translational Med (IF 15.8)
40. Chemical Science (IF9.21)
41. Nanoscale (IF7.37)
42. ACS Applied Materials & Interfaces
Abstracts Reviewer for Annual AAPS Conferences (2008-2010).
2005 Reviewer for 5-year NIH/NCI pharmacology/ toxicology contract research applications
2009-2010 Peer-reviewer invited by the Medical Research Council (MRC) of South Africa (a statutory science council that is responsible for managing and funding research in South Africa) to evaluate the merit of research proposals submitted for funding.
2012-2014 Invited grant reviewer for National Natural Science Foundation of China (NSFC)
2011 Invited reviewer for the young 1000-plan award
2013 Invited reviewer for Jiangxi Province Science and Technology Innovative Project applications
2014-2015   Invited Oncology Study Section Review Site Panel of the National Natural Science Foundation of China (NSFC)
2013-2016   Invited Oncology or Pharmacology Study Section Grant Application Reviewer of the National Natural Science Foundation of China (NSFC)
10/2014 Committee of the innovative pharmaceutical research of outstanding scientist award
2011-2014 Committee of the AAPS annual meeting abstract Award/ travelship
2013-2014 Reviewer for 2014 AAPS Research Achievement Award in Drug Discovery and Development Interface (DDDI)
Invited Speaker, Conference MODerate and ORGANIZER: 
1. Presentation entitled “Discovery of nitric oxide/ EDRF and its pharmacological effects” in East Hospital, Fuzhou, China, June, 1997.
2. Invited speaker, “S-nitrosylation and related drug discovery and development”, Nov. 1997, in Shenyang PHARON Health Products Co. LTD.
3. Invited speaker, presentation title “L-Arginine increases GFR partially by nitric oxide independent mechanism via activity of agmatine”.1998 American Society of Nephrology Annual Conference, Philadelphia, Oct. 25, 1998.
4. Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” State University of New York at Buffalo, Nov., 2001.  
5. Speaker, presentation title “EDRF Activity, Anticancer Spectrum and Pharmacokinetics of JS-K” NCI-SAIC Frederick, MD. Oct. 18, 2002.
6. Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” Johnson & Johnson Pharmaceuticals, San Diego, CA. Feb. 2002.  
7. Speaker, presentation title ‘Stability of JS-K in Biomatrices’ at NCI-SAIC Frederick, MD. Oct. 16, 2003.
8. Speaker, presentation title ‘Public-private partnerships for development of 2nd generation of ethambutol analogs for tuberculosis treatment’. Sequella, Inc. Rockville, MD, Dec. 2, 2003.
9. Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” in Division of Applied Pharmacology Research, OTR/OPS/CDER/FDA, April, 2004.  
10. Speaker, presentation title ‘Interspecies pharmacokinetics of SQ109 and its metabolism profile’ Sequella, Inc. Rockville, MD. Aug. 3, 2004.
11. Speaker, presentation title “In vitro and in vivo testing of JSK”. NCI-Frederick, MD 10/26/2006
12. Speaker, Moderator and Organizer, presentation title “GLP-Regulations and Inspections in USA and China: Differences, Similarities and Case Analysis” in the two-day conference “Pharmaceutical Outsourcing: Regulations, IP, Technology, Capabilities, and Partnership” Shanghai, China, April 2-4, 2007, co-sponsored by Fudan University (SPFDU) and AAPS.
13. Speaker, Moderator and Organizer, presentation title “New Drug Applications in USA and China: Acceptability, Data Requirements and Benefit/Risk Analyses” in the two-day conference “Pharmaceutical Outsourcing: Regulations, IP, Technology, Capabilities, and Partnership” Shanghai, China, April 2-4, 2007. I designed topics and agenda, invited prominent experts for presentations.
14. Moderator and Organizer of the symposium entitled “Exploratory IND (phase 0 trial) and its practices” at the 2007 annual National Biotechnology Conference. San Diego, CA June, 26. 2007. I designed topics and agenda, invited leaders from the FDA, NIH, and Pharmaceutics who drafted or implemented the Phase 0 trials for presentations.
15. Speaker, presented “Differences and similarities between USA and China in new drug application procedures and regulations”. Global R&D Congress, May 29-30, 2008, in Washington, DC,
16. Moderator: 2008 AAPS, November 19, 2008. Georgia World Congress Center, Atlanta, Georgia, USA. “Outsourcing Drug Product Development to India and China” (Roundtable).
17. Session Chair and Speaker, presented ‘Sino-USA collaboration: challenges and opportunities for advancing nanomedicine’, moderated a brainstorm panel session at The 1st Joint US-China Symposium on Nanobiology and NanoMedicine, Oct. 21-23, 2008; Fragrant Hill, Beijing, China;
18. Moderator and Speaker: “Celebrating the Nanotechnology R&D Act: Then, Now and the Future” (Symposium), 2008 AAPS, November, 20, 2008. Georgia World Congress Center, Atlanta, Georgia, USA.
19. Interviewed by Pharmaceutical Technology’s Live Vidcast, Nov. 18, 2008, on “Nanotechnology in Pharmaceutical Applications”. 
20. Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize In Medicine─Maximize Your Research Achievements By Publications And Networking” to the School of Pharmacy, Fujian Medical University, April 2, 2009.
21. Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize In Medicine─Maximize Your Research Achievements By Publications And Networking” to the Nanobiological Center of Shanghai University, April 6, 2009.
22. Invited speaker: “Differences and similarities in GLP-regulations and inspections between USA and China”, presented at Medicilon, Inc. April, 7. 2009.
23. Invited Speaker: “Comparison of new drug application procedures and regulations between USA and China” at “China 2009 Pharmaceutical R&D Summit” 4th International Conference & Exhibition, April 7-9, 2009 • Grand Hyatt Hotel • Shanghai, China.
24. Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize in Medicine─Maximize Your Research Achievements by Publications and Networking” to the School of Pharmacy Fudan University, April 9, 2009.
25. Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize in Medicine─Maximize Your Research Achievements By Publications And Networking” to the China Pharmaceutical University, April 10, 2009.
26. Seminar entitled “The Four-decade War on Cancer: Are We Winning???” presented to South China Center for Innovative Pharmaceuticals, Nov. 18, 2009.
27. Speaker, presentation title “Anti-HIV drug development involved in ADME and nanotechnology”, and moderator at International Symposium of NanoMedicine on AIDS/HIV sponsored by Beijing University of Technology, the National Center for Nanosciences and Technology of China, AAPS, Chinese Academy of Sciences and Chinese Ministry of Science and Technology (MOST), Beijing, China; Nov.19-20, 2009.
28. “Why we are not winning the war on cancer and how to lead the war to win: my view, my dreams and my strategies” presented at Graduate School of Pharmacy, Shanghai Jiao Tong University. Nov. 20. 2009.
29. Invited Speaker, “Contemporary understanding of the Millennium Phytomedicine― Ginseng” in Symposium: The Appalachian Center for Ethnobotanical Studies (ACES) in Tai Sophia Institute in Laurel, MD, on Saturday 26 June 2010. 
30. Invited Speaker, “The four-decade war on cancer: are we winning?” in Capital Medical University, Beijing, China. 10/25/2010, afternoon  
31. Invited Speaker, “The four-decade war on cancer: are we winning?” in Symposium 6: Advances of Drug Discover against cancers, The 8th Annual Congress of International Drug Discovery Science and Technology. 10/26/2010, 9:45-10:10 am  
32. Invited Speaker, “Current understanding of cancer metastasis requires changes in strategies of anticancer drug development”, in symposium 5 of annual Chinese Pharmaceutical Association Conference; Beijing, China, 11/7/2010, 9:15-9:35 am
33. Symposium: “Re-Engineering Nanomaterials with Biomolecules: Strategies, In Vivo Stability and Specificity, and Drugability", as both the moderator and speaker for the 2011 National Biotechnology Conference, Wednesday, May 18, 2011, from 1:30 pm - 4:00 pm, at the Hilton San Francisco, CA.
34. Invited Speaker, “From understanding the complex of cancer metastasis to designing cancer nanomedicine: what nanomedicines can and can’t succeed” and moderator of Nano-pharmaceutics Session at the International conference of 2011 China Nano, at the National Convention Center, Beijing. Sept.7-9, 2011.
35. Designed and Chaired the Hot topic: “The heating-up of pharmaceutical globalization:  current mergers and acquisitions by Chinese Pharma in the USA and basic knowledge of laws about drug importation to China”. October 24, 2011 12:15 PM – 1:30 PM, at the Walter E. Washington Convention Center, Washington, DC. USA (attendees 500)
36. Session Chair, Symposium: “Global Competition and Geopolitical Priorities for Bionanotechnology R&D”. 9:00-11:00 am, Oct 25, 2011. Convention Center, Washington DC, USA. The 2011 AAPS.
37. Speaker, Jia: “The market and contemporary understanding of the millennium phytomedicine-ginseng” and Session Chair “Evaluating Drug Development Opportunities in Botanical Polymolecular Therapeutics”. Time: Wed. 8:30-11:00 am, 10/26/2011; Place: Washington DC convention CTR.
38. Speaker, Jia: “Overview of Global Development of Photodynamic Therapy for Cancer and   China’s First Generation of Photosensitizer ZnPcS2P2” and co-Chaired the session “Nanobiotechnology” with Dr. Chen Wang, Director, National CTR for Nanoscience & Technology; 19:20-22:00, Oct. 31, 2011. 17th International Biophysics Congress, Beijing.
39. Invited speaker “Contemporary understanding of the nutraceutical ginseng: its anti-diabetic and cancer preventive effects and possible interaction with Warfarin”, and Session Chair “2012 International Conference on Ginseng”, Jilin, Chair; Sept. 4-7, 2012. (260 Attendees)
40. Invited speaker and organizer “The 40-year war on cancer: are we winning or Losing, and our strategies” at Fujian Pharmacological Society Conference (150 attendees), Fuzhou, Nov. 17th, 2012. Fujian Pharmacology Society, China.
41. Invited speaker “Re-engineering PAMAM dendrimer for its multivalent binding to colon cancer cells HT29” at The 3rd Joint US-China Symposium on Nanobiology and NanoMedicine, Dec. 5-7, 2012; Fragrant Hill, Beijing, China; 第449次北京香山科学会议、即第3次中美癌症纳米技术和纳米医学研讨会(2012年12月5-7日)
42. Invited speaker “Restrain activity of circulating tumor cells: the new strategy for preventing cancer from metastasis” at the China-US translational medicine international forum (250 attendees), 中国科协15届年会 (Chinese Association of Scientists);Guiyan medical university, May 25, 2013.
43. Invited speaker “The new strategy to prevent cancer from metastasis: restrain circulating tumor cells” at the 2013 AAPS@ China Symposium, the Chinese University of Hong Kong, August 17-18, 2013.
44. Invited speaker and organizer “From endothelium-derived relaxing factor (EDRF)
to intervention of adhesion-invasion of circulating tumor cells (CTCs) to endothelium: a new horizon in biomedical nitric oxide research” at the 2014 International Nitric Oxide Conference, Shanghai Jiaotong University. July 5-6th, 2014.
45. Invited speaker and Section Chair: “Enhanced sensitivity and specificity of capturing and restraining circulating tumour cells in blood with dual antibody-coated nanomaterials” China Nanobiomedicine conference, Chenddu, 2014-11-05 China nanobiology and nanomedicine conference (全国纳米生物与医学学术会议-成都)
46. Invited speaker and Section Chair: “Nitric oxide prevents cancer metastasis by interrupting adhesion-invasion of circulating tumor cells to endothelium” in the 8th Pong Ding Yuen International Symposium on Traditional Chinese Medicine cum The 2nd International Chinese Symposium on Free Radical Research & The 6th Symposium for Three Districts of Cross-straits on Free Radical Research; University of Hong Kong, November 14-16, 2014.
47. Invited speaker “From endothelium-derived relaxing factor (EDRF) to intervention of adhesion-invasion of circulating tumor cells (CTCs) to endothelium: a new horizon in biomedical nitric oxide research” Chinese Pharm. University. Nov. 17, 2014.
48. Invited speaker: “Nitric oxide prevents cancer metastasis by interrupting adhesion-invasion of circulating tumor cells to endothelium” Fujian Chinese Medicine University. Nov. 20, 2014.
49. Invited speaker: “From Imitation to Innovation: the Ten-year Chinese Bionanotechnology Development” China Nanomedicine Conference, Hangzhou, April 7-9, 2015
50. Invited speaker: “The unique bionanotechnology conception focuses on cancer pre-metastatic prevention for tens of millions of survivorship" Nature Nanotechnology Forum at Fudan University, May 25th, 2015.
51. Invited speaker: “Separation, detection, capture and restraining of circulating tumor cells for cancer metastasis prevention for the increasing cancer survivors”BD Shanghai July 2015
52. Invited speaker: “Bionanotechnology used for capturing and restraining circulating tumor cells: eliminating the suffering and death from cancer metastasis” Dong, HY., Lu, Y., Xu, JG., Zheng, N., Liu, J. Jia,*L. ChinaNano 2015 meeting; Sept. 3-5, Beijing
53. Invited speaker: “Development of theranostical nanomedicine to specifically target circulating tumor cells (CTCs)” Jianguo Xu, Haiyan Dong, Yusheng Lu, Ning Zheng, Jian Liu, Lee Jia* 2015年中华放射学会年会,哈尔滨,9月17-20日“精准与可视化”专题
54. Invited speaker: “避孕药美她司酮用于二性预防肿瘤手术后的再转移:研究背景、现状、及其药代动力学的性别特征”. 中国药理学会全国药代动力学会议;济南,2015-10-10/12.分会场主持。
55. Invited speaker: “Novel strategy: shifting from traditional anticancer drugs and nanomedicines to circulating-tumor-cell-based metastasis chemoprevention (创新研发战略:从传统的抗癌药和纳米药物向基于循环肿瘤细胞的肿瘤转移的化学预防转变”。Suzhou Institute of Nano-Tech and Nano-Bionics Chinese Academy of Sciences, Oct., 13th, 2015.
56. Invited speaker: “Overview of Global Development of Photodynamic Therapy for Cancer and Our Contribution to Biopharmaceutical Photocatalysis” at the 2nd Fuzhou University-Osaka Prefecture Uni. Joint International Symposium. Oct., 30th 2015;Fuzhou Uni.
57. Invited speaker: “from the 1971 Cancer Act and NCI founded to today’s global cancer therapy: cancer metastatic alert and chemoprevention”. Aug. 6-7th 2016; Beijing; PLA 302 Hospital. The first NIH/USA overseas returnee scholar forum.
58. Organizer and Invited speaker: “Global deregulation of ginseng products may be life-threatening to warfarin takers: solid evidence of serious ginseng-warfarin interaction” International Conference on Ginseng 2016 Jilin, China; Sept. 6-9, 2016; Changchun.  
59. Invited speaker: “From the ineffective post-metastatic anticancer chemotherapy to pre-metastatic chemoprevention: the conceptual change” Nov. 19th 2016; Chongqing; The second NIH/USA overseas returnee scholar forum.
60. Organizer and speaker: “Bionanotechnology and Cancer Pre-metastatic Chemoprevention”. The Fourth Annual Conference of Chinese Society of Micro- & Nanoscience and Technology/ the 2016 International Conference of Nanobiology and Nanomedicine. Fuzhou, Fujian, China. Dec. 7-10, 2016.
61. Invited speaker: 从源头遏制肿瘤转移的瀑布反应:预防肿瘤转移的创新战略。福建放疗、免疫治疗圆桌会2017年3月30日Fuzhou
62. Invited speaker: Bionanomaterials for Specifically Binding and Inhibiting Circulating Tumor Cells in Vivo. Xiamen University, Xiamen. April 10, 2017.
63. Invited speaker: Restrain CTCs by dual aptamer-conjugated dendrimers with enhanced capture specificity. The 7th ChinaNano international conference, Beijing, Aug. 30, 2017
64. Invited speaker: 肿瘤治疗:慢性病防控的创新思维可望显著减少全球肿瘤死亡2017第二届创新药物研发与应用大会;Nanjing, 10/23, 2017.
65. Invited speaker:  肿瘤治疗:慢性病防控的创新思维可望显著减少全球肿瘤死亡, China Pharmaceutical University; Nanjing, 11/3, 2017
PRE-IND Packages and Meetings with FDA and IND APPLICATIONS:
1. Pyrrolobenzodiazepine (SJG-136), Preclinical pharmacology summary prepared by Jia. (Date filed: July 14, 2004; FDA IND# 70218; FDA approved August 13, 2004)
2. Pre-IND packages and meetings with FDA and Sponsors: LIV-1, a novel drug delivery system to deliver 5-FU to hepatocytes and hepatoma cells to treat hepatocellular carcinoma (HCC). Cell-Works, Inc. Feb, 2003.
3. R(-)Gossypol (AT-101), FDA IND# 68255: Pharmacology Summary prepared partially by Jia; Sponsor: Ascenta Therapeutics, 2005.
4. SQ109, FDA IND# 69597: Pharmacology Summary prepared by Jia; Sponsor: Sequella, Inc. Filed in Sept. 2006.
5. MV-NIS virus, a live tissue culture adapted measles virus selectively targeting human myeloma cells. FDA IND# 13023. May 3rd, 2006.
6. Batracylin (NSC 320846): Pharmacology and Toxicology Summary prepared by Jia for IND filing; IND# 76254; Sponsor: National Cancer Institute. Completed in March, 2006.
7. 1-methyl-[D]-tryptophan (NSC721782; IND#78060): Pharmacology and Toxicology Summary prepared by Jia for IND filing; Sponsors: NCI and NewLink Co. Completed Aug., 2006. IND meeting: July 19, 2007.
8. P-28 peptide (IND# 77754) Pre-IND meeting with FDA July, 12, 2007; IND submitted July 8, 2008.
9. Development of allopregnanolone in Neiman-Pick type C disease (NP-C) PIND-74900 for treatment of inherited mitochondrial respiratory chain diseases; Pre-IND on Oct 17, 2006; White oak, Building 22/FDA; Sponsor: Edison Pharm.
10. Pre-IND meeting with FDA for single chain urokinase plasminogen activator (ScuPA) (PIND 106014) development; Oct. 27, 2009.
11. Pre-IND meeting with FDA for SPINALON designed to prevent or reverse chronic immobility-related health problems typically found in spinal cord-injured patients; Jan. 14, 2010.
12. Pre-IND meeting with FDA for development of PEG-hemoglobin-based oxygen carriers (HBOC) for AfterShock treatment; Feb., 23, 2010, at FDA Woodmont Office Building, Rockville, MD.
1. Jia, L.: Method of synthesis of S-nitrosocaptopril crystals and the use thereof (issued as both the inventor and owner: CO7D207/16).
2. Jia, L. Garza, M, Wong, H, Redelmeier, T.E.: Intravenous carbendazim compositions (filed as inventor).
3. Jia, L: Method and compounds that prevent circulating tumor cells from adhesion and extravasations to distant organs (filed as the inventor and owner: file # 201110338508.9) 专利授权号:ZL 2011 10338508.9 干预循环肿瘤细胞粘附和浸润到外周组织的药物和新方法。
4. Jia, L.: Medicinal combination that prevent cancer metastasis after surgical removal of primary tumors (filed as the inventor and owner: file # 201210379714.9) 专利申请号201210379714.9   预防原发性肿瘤在手术切除后再转移的药用组合物
5. 陈海军,贾力(Lee Jia),刘剑,俞雪梅, 陈晓云,黄惠龄、王继闯,高瑜。一种合成美她司酮的方法专利授权号(patent issued#:ZL 2013 1 0510394.0.‍ (Method of synthesis metapristone;
6. 高瑜,李志洪,王超群,陈海军,贾力。具有肿瘤靶向的叶酸-PAMAM-熊果酸纳米药物及其制备方法。专利授权号:ZL201410271351.6。
7. 高瑜,吴福强,顾颂恩,李志洪,解晓东,陈海军,贾力。一种米非司酮脂质体制剂及其制备方法。申请号:201410219537.7。
8. 高瑜,贾力,顾颂恩。一种抗体偶联的介孔二氧化硅/米非司酮纳米制剂。申请号:201510635471.4.
9. 江舟,杨纪娜, 庞雅琼, 王建, 贾力(Lee Jia). “一种九里香香豆素及其提取方法”中国专利授权号(patent issued#:ZL 2015 1 0003203.0; Method of extracting coumarins from Murraya exotica).
10. 贾力(Lee Jia),卢余盛,于婷,梁海燕。斯诺普利在制备预防肿瘤转移或肿瘤治疗药物中的应用。专利授权号(ZL 201410609416.3)  Method of using S-nitrosocaptopril for  cancer metastasis prevention or cancer treatment)
11. 贾力(Lee Jia)、谢静静、陈红宁; 专利名称:识别、捕获和抑制循环肿瘤细胞的功能纳米材料载药系统;专利申请号(patent file#:201410639414.9; Functionalized nanomaterial carrier for recognizing, capturing and inhibiting circulating tumor cells)
12. 江舟,庞雅琼,周素霞,王建,贾力(Lee Jia); 专利名称:六甲氧基二氢黄酮-鼠李糖基-鼠李糖苷在肿瘤转移预防中的应用(patent file#:201510596604.1)
13. 江舟,马骁,张俨君,王锐,王建,余素红,贾力..怀牛膝和川牛膝中的牛膝皂苷 (已公示)。
14. 贾力  杨静毅,钱钧,江舟,石庆2016-9-19 专利申请号2016108294746 人参皂苷R0在制备肿瘤转移预防药物中的应用
15. 贾力、董海燕、王杰、韩龙宇一种检测哺乳动物血液中微量循环肿瘤细胞的特异性方法;专利申请号201610858045.1  
16. 贾力 董海燕、张婷: 一种纳米-双环状适配体探针及其应用. 专利申请号201611169875X; 2016-12-16
17. 高瑜,黎凤乔,梅淏,解晓东,贾力。一种适配体修饰的携氧载药多功能脂质复合物的制备及其在逆转肿瘤耐药中的应用。(申请号尚无,等申请后告知)
18. 高瑜,解晓东,黎凤乔,贾力。一种双适体修饰的介孔二氧化硅纳米载体及其在制备抗肿瘤转移药物中的应用。(申请号尚无,等申请后告知)
19. 贾力、余素红、贺苏丹、李书慧。一种可抑制富含巯基的肿瘤细胞的侵袭和转移能力的方法及其应用
Managed and directed NIH Contract research Funding
1. Southern Research Institute (NO1-CM-52203) Total budget $ 2,774,595 from 2005-2011 for preclinical pharmacological studies of antitumor and other therapeutic agents.
2. Mayo Clinic (NO1-CM-52206) Total budge $1,828,875 from 2005-2011 for preclinical pharmacological studies of antitumor and other therapeutic agents.
3. University of Alabama at Birmingham (NO1-CM-52207) Total budget $ 1,714,794 from 2005-2011 for preclinical pharmacological studies of antitumor and other therapeutic agents.
1. Title: Nitric Oxide in Apoptosis: S-nitrosocaspases and Cytochrome C (Jan. 1998) PI: Jia, L.
CA-98-003, Outstanding Scholars Program (K22), Supported by NCI. $150,000/year for 4 yr.
2. Title: Development of a proteomic database for cancer prevention and treatment (Feb. 2001) PI: Jia, L. 5% effort, Supported by SACI. $21,500 for one year.
3. Title: Pharmaceutical development of 301029, an antiviral drug (March, 2000-June, 2001) PI: Jia, L., Supported by The Procter and Gamble Co. P&G 250-259. $350,000
4. Title: Pharmaceutical development of FB642 (Carbendazim) as an anticancer drug (May, 2000- Sept. 2001) PI: Jia, L., Supported by The Procter and Gamble Co. P&G 210-233. $ 550,000.
5. Title: Dynamic analysis of pharmacoproteomic effects of docetaxel and nitric oxide on prostate cancer cells (March 21, 2001) PI: Jia, L. 25% effort, PC010169; Submitted to Department of Defense, Prostate Cancer Research Program. $326,085 for 3 yrs.
6. Title: Urinary proteomic analysis of normal and prostate cancer patients using LC/MS/MS (Nov. 2, 2001) PI: Jia, L. Submitted to SA Area Foundation $34,700 for one year.
7. Title: Discovery of novel prostate cancer biomarkers from patient’s specimens by LC/MS/MS-based proteomics (January 30, 2002) PI: Jia, L. Cancer Center Council $46,050/year.
8. Title: Anti-tuberculosis SQ109 development (Sept. 2003-Feb. 2005); co-PI: Jia, L 15% effort; $211,900, NO1-CM-07710, NO1-CM-52203;
9. Title: PK/PD study with GGTI inhibitor GGTI-2418 (10/2005-1/2007); PI $87,387; NO1-CM-52203;
10. Title: Development of Phor21-BCG(ala), a lytic peptide conjugate (04/2004- 10/2004); PI $112,000, NO1-CM-07110.
11. Title: Development of pro-apoptotic Apogossypol, a Gossypol metabolite (08/2004- 11/2005); PI $190,000; NO1-CM-52203; NO1-CM-52205; NO1-CM-07110.  
12. Title: Anticancer drug 1-methyl-D-trytophan development (02/2004-04/2007); PI, $180,000, NO1-CM42201; NO1-CM52206; NO1-CM-07105.
13. Title: Anticancer dimeric pyrrolobenzodiazepine SJG-136 PK/PD characterization (12/2002-06/2003); PI, $183,740; NO1-CM-07105.
14. Title: Nitric oxide prodrug JS-K pharmacology and formulation development (08/2002-06/2009); PI, $237,000; NO1-CM-52206; NO1-CM-07105.
15. Title: Azurim p-28 toxicology, pharmacology and metabolism (06/2007-05/2008); PI, $92,790; NO1-CM-52203.
16. Title: Pharmacology of the novel investigative anti-cancer indolecarboxamide ML-970 (03/2008- 09/2009); co-PI, $363,000; NO1-CM-52207.
17. Title: Safety evaluation of new formulations (11/2007-05/2008); PI. $346,560; NO1-CM-52203.
18. Title: Patient pharmacokinetics of Topotecan and PARP inhibitor ABT888 (05/2007-12/2009); co-PI. $173,500; NO1-CM-52206.
19. Fuzhou University Start-up fund ¥10 millions (01/2012-present)   
20. Title:Interference by nitric oxide with adhesion of circulating tumor cells to vascular endothelium (01/2013-12/2016). PI. Natural Science Foundation of China NSFC81273548. ¥650,000.
21. Title: Innovative research team start-up fund; PI¥1.5M, 2013-2014; from the China Finance Department of Central Government.   
22. 973 program: 项目编号:Ministry of Science and Technology of China (2015CB931804); Project title: Basic research for novel nanomaterial image probes for in vivo lung cancer classification 2015/01—2019/12; Sub-project title: Lung cancer personal treatment and resultant evaluation based on in vivo lung carcinoma classification. 项目名称:肺癌在体分子分型的新型纳米分子成像探针基础研究; 课题组: 基于在体分子分型的肺癌个体化治疗及评价; 项目起止时间:2015年1月-2019年12月; ¥5.25 millions.
23. Fujian Development and Reform Commission project# 829054(2014;168); ¥500,000; Development of novel cancer metastasis chemopreventive agent Metapristone; period, 2014-2016.
24. NSFC program: Frontier researches on bioactive materials extracted from Murraya paniculata widely-grown in Fujian and Taiwan, their mechanism of actions and drugability used for cancer metastasis chemoprevention after operation(闽台盛产九里香用于预防肿瘤手术后再转移的药效物质基础、作用机制及其成药性的前沿研究) U1505225; ¥2.58M, 2016.01 to 2019.12
25. NSFC program: Similarities between adhesion of circulating tumor cells to vascular endothelium and implantation of blastocyst to endometrium: the novel conception of pre-metastasis chemoprevention。项目批准号:81773063,项目名称:循环肿瘤细胞在血管内膜的粘附和孕卵在子宫内膜的着床的相似性:预防肿瘤转移的新思路; Direct cost:55万元,项目起止年月:2018年01月至 2021年 12月.


 1.         Jia, L*. 雷公藤属植物的化学、药理和临床应用。药学通报 1985;20(2):101-106。
2.         Jia, L*. 雷公藤甲素注射液的稳定性试验《中国药学杂志》 1985年10期.                    
3          Jia, L* Probit analysis of LD50 of triptolide and its cytotoxicity.  Chinese J. Pharmacol Toxical.  1: 78-80, 1986.
4.         Jia, L* Studies on angiotensin converting enzyme inhibitors. Prog. Physiol. Sci. 6:229-234, 1985.        
5.         Jia, L* Hoe, D. H.: Negative chronotropic effects of meglumine cyclic adenylate on cardiac pacemaker in vitro and in vivo.    Acta  Pharmacol  Sin   9: 421-426, 1988.
Jia, L*, Hoe, D. H.: Antiarrhythmic effects of meglumine cyclic adenylate. Chinese J. Pharmacol. Toxical.  3: 251-255,1989.
7.         Jia, L*,  Hoe, DH. Effects of meglumine cyclic adenylate on contractility, oxygen consumption and excitability of Langendorff heart and cardiac cells.  Chinese J. Pharmacol. Toxicol. 2:16-19,1988.
8.         Jia, L*. Hoe, DH. Effects of meglumine cyclic adenylate on drug-induced positive chronotropic action in rabbit right atria.  Chinese J. Pharmacol  Toxicol.  2: 235-238, 1988.
9.         Jia, L.: Adenosine Receptors and adenosine pharmacology.    Chinese  Pharmacol.  Bull. 5: 129-133, 1989.
10.       Jia, L and Furchgott RF. Inhibition by sulfhydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor  J. Pharmacol. Exp. Ther. 267:371-378, 1993   
11.       Jia, L* Liu, X., Furchgott RF.  Blockade of nitric oxide-induced relaxation of rabbit aorta by cysteine and homocysteine. Acta.  Pharmacol.  Sin. 18(1):11-20, 1997.           
12.       Jia L, Bonaventura, C., Bonaventura, J. and Stamler, J. S.: S-nitrosohemoglobin:  a dynamic activity of blood involved in vascular control.        Nature    380: 221-226, 1996                
13.      Simon, D.I., Mullins, M.E., Jia, L., Gaston, B., Singel, D. J., Stamler, J.S.: Polynitrosylated Proteins: Characterization, bioactivity and functional consequences.  Proc. Natl. Acad. Sci. U.S.A.  93: 4736-4741, 1996.
14.      Day, B J, Jia L, Arnelle DR, Crapo, JD, and Stamler, JS.: Transduction of  NOS activity from endothelium to vascular smooth muscle: involvement of S-nitrosothiols  In  Biology of NO, ed. by Moncada, Stamler, Gross and Higgs, pp. 202-4  Portland Press, London, 1996.
15.       Jia, L* Clinical trials and therapeutic implications of nitric oxide and its donors.  Pharmaceutical Commun Sin. (Review).     13: (3) 204-206, 1997, 
16.       Stamler, J.S., Jia, L., Eu, J.P., McMahon, T.J., Demchenko, I.T., Bonaventura, J., Piantadosi, C.A.: Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient.    Science. 276: 2034-2037, 1997.
17.       Lin, M, Yang X, Wang, J., Jia, B.J., Jia,*L. Inhibitory effects of S-nitrosocaptopril on vasomotor tone.  Acta Pharmacol  Sin.    1998, 19 (5): 485-488.
18.       Jia, L* and Stamler, J. S.: Dual actions of S-nitrosylated derivative of vasoactive intestinal peptide as a vasoactive intestinal peptide-like mediator and a nitric oxide carrier.  Eur.  J.  Pharmacol   1999, 366: 79-96.
19.       Lin, M, Yang X, Wang, J., Jia, B.J., Jia,*L. S-nitrosocaptopril preferentially decreases diastolic pressure in hypertensive models. Chinese Pharm. Bulletin  1999, 15(1) 73-76. 
20.       Jia,L*., Blantz, RC. The effects of S-nitrosocaptopril on renal filtration and blood pressure in rats  Eur  J. Pharmacol. 1998, 354: 33-41.
21.       Jia, L*. Young, X, Guo, W:  Physicochemistry, pharmacokinetics and pharmacodynamics of S-nitrosocaptopril crystals, a new nitric oxide donor    J.  Pharm.  Sci.  1999, 88: 981-986.
22.        Jia, L* A design of a novel compound S-nitrosocaptopril possessing the capacities of both angiotensin converting enzyme inhibitors and nitric oxide donors. Prog. Physiol. Sci. 1999, 29: 12-15.
23.       Jia, L* Nitric oxide research and new drugs: Challenges and success. Commentary on the 1998 Nobel Prize in Medicine.   Science (in Chinese) 1999, 51(2): 49-52.
24.      Lin, M., Jia, L*. International principles of nomenclature and abbreviations of nitric oxide research. Prog. Physiol. Sci. 1999, 30(4): 376-78. 
25.     Jia, L*, Yu, L. Linnik, D.M., Jack, R.M.  Stability and Pharmacokinetics of LJP 920, an octameric Gal (a1-3) Gal conjugate for the inhibition of xenotransplantation rejection.   J. Pharm. Pharmacol. 53: 999-1005, 2001.
26.     Jia, L*. Wu, C. Young, X: Anti-angiogenetic effects of S-nitrosocaptopril crystals as a nitric oxide donor.  Eur.  J.  Pharmacol.  391: 137-144, 2000.
27.     Jia, L*. Pei, R. Lin, M. Young, X. Acute and subacute toxicity and efficacy of S-       nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities.  Food &        Chem. Toxicol. 39: 1135-1143, 2001.
28.     Jia, L*. Garza, M. Wong, H. Camden, J. Redelmeier, T. Weitman, S. Pharmacokinetic       comparison of intravenous carbendazim and remote loaded carbendazim liposomes in   nude mice.  J. Pharm. Biomed Anal. 28(1): 65-72, 2002.

Wong, H. Jia, L*. Camden, J. Weitman, S. Liquid chromatography-mass spectrometry assay of a thiodiazole derivative in mice: application to pharmacokinetic studies.  J. Chromatogr. 765:55-62, 2001.

30.     Jia, L*. Wong, H. In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S-nitrosylated captopril, a nitric oxide donor. Br. J. Pharmacol. 134: 1697-1704, 2001

31.     Jia, L*. Wong, H. Cerna, C. Weitman, S. Effect of nanonization on absorption of 301029: Ex vivo and in vivo pharmacokinetic correlations determined by LC/MS. Pharm. Res. 19:1091-1096, 2002.

32.     Jia, L*. Wong, H. Wang, Y. Garza, M. Weitman, S.  Carbendazim: Disposition, cellular permeability, metabolite identification and pharmacokinetic comparison with its nanoparticle. J. Pharm. Sci. 92:161-172, 2003.

33.     Jia, L*. Schweizer, J. Cerna, C. Wong, H. Revilla, M. Effect of Nitric Oxide on Cytotoxicity of Taxol: enhanced Taxol transcellular permeability. Biochem Pharmacol. 66:2193-2199, 2003.

34.     Jia,*L., Spanswick, VJ., Reid, JM., Kuffel, M., Buhrow, SA., Ames, MM., Hartley, JA.,  Thurston, DE., Tomaszewski, JE. Use of the comet assay as a surrogate biomarker for the in vivo measurement of DNA damage to lymphocytes. Cancer Research 2004; 64(7 Supplement) 452-453.

35.     Jia, L*. Tomaszewski, J.E., Noker, P.E., Gorman, G.S., Glaze, E., Protopopova,M. Simultaneous determination of pharmacokinetic properties of three anti-tubercular ethambutol analogs resulting from combinatorial lead optimization. J. Pharm. Biomed Anal. 37(2), 23-33, 2005.

36.     Jia, L*. Tomaszewski,J., Hanrahan, C. Coward, L. Noker, P. Gorman, L. Nikonenko, B. Protopopova, M. Pharmacodynamic and pharmacokinetic characteristics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144, 80-87, 2005.

37.     Jia, L*. Coward, L. Gorman, L. Noker, P. Tomaszewski, J. Pharmacoproteomic effects of isoniazid, ethambutol, and N-Geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.  J. Pharmacol. Exp. Ther. 315, 905-911, 2005.

38.     Saavedra, J.E., Srinivasan, A., Buzard, G.S., Davies, K.M., Waterhouse, D., Inami, K., Wilde, T.C., Citro, L.M., Cuellar, M., Deschamps, J.R., Parrish, D. Shami, P.J., Findlay, V.J. Jia, L., Ji, X., Keefer, L.K., PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity.  J. Med. Chem49, 1157-1164, 2006.

39.      Jia, L*. Global governmental investment in nanotechnologies. Curr. NanoScience (Review) 1:(3) 263-266, 2005.

40.      Jia, L*. Nanoparticle formulation Increases oral bioavailability of poorly soluble drugs: experimental evidences, theory, and approaches. Curr. NanoScience (Review) 1:(3) 237-243, 2005.

41.      Coward, L.C. Kerstner-Wood, Noker, P., Gorman, G., Pellecchia, M., Reed, J.C., Jia, L*. Quantitative determination of Apogossypol, a pro-apoptotic analog of gossypol, in mouse plasma using LC/MS/MS. J. Pharm. Biomed. Anal. 42: 581-586, 2006.

42.      Jia, L.*, Noker, P.E., Coward, L. Gorman, G. Protopopova, M., Tomaszewski, J.E. Interspecies pharmacokinetics and in vitro metabolism of SQ109   Br. J. Pharmacol. 147(5):476-85, 2006.

43.      Buhrow, S.A., Reid, J.M., Jia, L., Covey, J., Kobs, D.J., Grossi, I. M., Ames, M.M. LC/MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501).  J. Chromatogr.  2006; 840: 56-62.

44.      Shami, PJ., Saavedra, J. E., Bonifant, C. L., Chu, J.; Udupi, V.; Malaviya, S.; Carr, B. I.; Kar, S.; Wang, M.; Jia, L.; Ji, X.; Keefer, L. K. Antitumor Activity of JS-K [O2-(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and Related O2-Aryl Diazeniumdiolates in Vitro and in Vivo.  J. Med. Chem. 2006; 49(14); 4356-4366.

45.      Jia, L. Pharmaceutical Globalization: First International CRO/CMO Conference sponsored by the AAPS in China.  AAPS NewsMagazine 7(3): 67, 2007.

46.      Jia, L*, Wang, Y., Zhu, YZ.  Pharmaceutical globalization urges cooperation between China and USA on GLP regulations. Chinese Medicine & Drugs Newspaper, March 22, 2007

47.      Jia, L*., Zhu, Y., Wang, Y., Wu, W., Dong, Y.C., Zhang, R., Fu, L., Bi, H., Tam, J. Harmonising GLP rules in the US and China: The globalisation of the pharma industry means China and the US need bilateral agreements on GLP regulations. The Regulatory Affairs Journal  18(3):147-152, 2007.

48.      Liu, X.D., Jia*, L. The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies. Curr. Drug Metab.  8: 815-821, 2007.

49.      Jia, L*., Liu, X.D. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr. Drug Metab.  8: 822-829, 2007.

50.      Jia, L.*, Schweikart, K., Tomaszewski, J., Reed, J., Ames, M, Page, J.,Noker, P., Munn, D. Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption.   Food Chem. Toxicol. 46: 203-211, 2008.

51.      Jia, L.* Coward, L.C. Kerstner-Wood, Gorman, G., Noker, Kitada S, Pellecchia M P., Reed, J.C., Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.  Cancer Chemotherapy Pharmacol. 61: 63-73, 2008.

52.      Liu, H.Y., Liu, X.D., Jia, L., Liu, Y.C., Yang, H.W., Wang, G.J., Xie, L.  Insulin therapy restores impaired function and expression of P-glycoprotein in blood–brain barrier of experimental diabetes.  Biochem. Pharmacol. 75: 1649-1658, 2008.

53.      Jia*, L., Noker, P.E., Piazza, G.A., Leuschner, C., Hansel, W., Gorman, G.S., Coward, L.U., Tomaszewski, J. Pharmacokinetics and Pharmacodynamics of Phor21-βCG(ala), a lytic peptide conjugate. J. Pharm. Pharmacol. 60:1441-48, 2008.

54.      Liang, X.J., Chen, C.Y., Zhao, Y.L., Jia, L., Wang, P.C. Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials.  Curr. Drug Metab. 9(8): 697-709, 2008.

55.      Jia, L*. Drug discovery and development operations in emerging regions: global R&D congress. Thomson-Pharma, June, 2008 (invited conference proceedings)

56.      Song, M., Wang, L., Hang, T., Wen, A., Yang, L., Jia, L. Rapid and sensitive liquid chromatography-tandem mass spectrometry for rasagiline: assay development, validation and application to a human pharmacokinetic study.  J. Chromatogr. 875:515-521, 2008.

57.      Jia, L. The Great Meeting Held in the Bitter Cold Economic Climate: 2008 AAPS Annual Meeting and Exposition. Thomson-Pharma, December, 2008 (invited conference proceedings)

58.      Kitada, S., Kress, C.L., Krajewska, M., Jia, L., Pellecchia, M., Reed, J.C. Bcl-2 antagonist ApoGossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with less toxicity compared to Gossypol (NSC19048).  Blood, 2008; 111: 3211 - 3219.

59.      Zhang, TT., Song, M., Hang, HJ., Xu, XF., Wen, A.D.,Yang, L., Jia, L*. Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa). J. Clin. Pharm. Ther.  33, 1-10, 2009.

60.      Jia* L. Zhao, YQ. Current Evaluation of Ginseng (I): Etymology, Pharmacognosy, Phytochemistry, Market and Regulations. Curr. Med. Chem. 16: 2475-2484, 2009.

61.      Jia*, L, Zhao, YQ. Liang, X.J. Current Evaluation of the Millennium Phytomedicine― Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine.  Curr. Med. Chem. 16: 2924-2942, 2009.

62.      Ni. L., Yu, X.,Yu, Q.,Chen, X., Jia, L*. Effects of cyclosporine A and itraconazole on permeability, biliary excretion and pharmacokinetics of amlodipine.  Drug Metab. Lett. 2(3): 163-168, 2008.

63.      Meng, J., Wang, D.L., Wang, P.C., Jia, L., Chen, C., Liang, XJ. Biomedical Activities of Endohedral Metallofullerene Optimized for Nanopharmaceutics. J. NanoSci NanoTech., 10: 8610-7, 2010.

64.      Jia*, L. Soldati, F. Ginseng, Asian (Panax ginseng); In Encyclopedia of Dietary Supplements. Ed by Coates PM. 2nd edition, pp.352-366, 2010; Informa Healthcare, New York, London. (Invited review).

65.      Jia* L, Gu Y., Zeng E, Linnik, MD, Jones, DS. Biostability, Tissue Distribution and Disposition of LJP 993, a Tetrameric Conjugate of Domain 1 of b2-glycoprotein I for antiphospholipid syndrome. Lupus. 19: 130-137, 2010.

66.      Kiziltepe, T., Anderson, K.C., Kutok, J.L., Jia, L., Saavedra, J.E., Keefer, L.K., Shami, P.J. JS-K has potent anti-angiogenic activity in vitro and inhibits tumor angiogenesis in a multiple myeloma model in vivo. J. Pharm. Pharmacol 62: 145-151, 2010.

67.      Liang, XJ., Meng, H., Wang, Y., He, H., Meng, J., Lu, J., Wang, P., Zhao, YL., Gao, X., Sun, B., Chen, CY., Xing, GM., Shen, DW., Yin, JJ., Gottesman M., Jia, L.  Metallofullerene Nanoparticles Overcome Tumor Resistance to Cisplatin by Reactivating Endocytosis. Proc. Natl. Acad. Sci. U.S.A. 107: 7449-7454, 2010.

68.      Tan, J.J., Cong, X.J., Hu, L.M., Wang, C.X., Jia, L, Liang, X.J. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discovery Today  15: 186-197; 2010.

69.      Ma, X.W., Wang, D.L., Wu. Y., Ho, R.J.Y., Jia, L., Guo, P., Hu, L., Xing, G.M., Zeng, Y., Liang, X.J., AIDS Treatment with Novel Anti-HIV Compounds Improved by Nanotechnology. The AAPS Journal 12, 272-278, 2010.

70.      Gorman, G., Coward, L., Kerstner-Wood, C., Noker, P., Beattie, C.W., *Jia, L. A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice J. Pharm. BioMed. Anal. 53: 991-996, 2010.

71.      Wang, YZ., Ma, XW., Ma, HL, Wang DL., Lu, J., Jia, L., Duan, XL., Liang, XJ. Specific hemosiderin deposition in spleen induced by a low dose of cisplatin: altered iron metabolism and its implication as an acute hemosiderin model. Curr. Drug Metabo. 11, 507-515, 2010.

72.      Tang, W., Jia, L., Zhao, Y. The newly-found bioactivities and clinical uses of ginseng and ginsenosides. Ginseng Res. 22(2): 32-38, 2010.

73.      Jia,*L. Qian K. An Evidence-based Perspective of Ginseng as a Preventing or Supplementary Therapy for Cancer Patients. In Evidence-based Anticancer Herbal Medicine., Ed., by W. Cho, Springer Science. 85-95, 2011.

74.      Jia, L*, Zhao, YL, Liang, XJ. Fast Evolving Nanotechnology and Relevant Programs and Entities in China. Nano Today 6: 6-11, 2011.

75.      Reid, J.M., Buhrow, S.A., Kuffel, M.J., Jia, L.  Spanswick, V.J., Thurston, D.E., Tomaszewski, J.E., Ames, M.M. Pharmacokinetics, Pharmacodynamics and Metabolism of the Dimeric Pyrrolobenzodiazepine SJG-136 in Rats. Cancer Chemother. Pharmacol. 68: 777-786, 2011.

76.      Jia, L., Gorman, G., Coward, L., Noker, P., McCormick, D.L., Horn, H.L., Harder, J.B., Muzzio, M., Prabhakar, B., Balaji, G., Gupta, T.K.D., Beattie, C.W.
Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination
Cancer Chemother. Pharmacol. 68: 513-24, 2011.

77.      Xu Z., Jia L., Zhao, YQ. Ginseng etymology, pharmacognosy, and the evaluation of its current products and markets. Modern drugs & Clin. 2:1-6, 2011.

78.      Xu, Z. Jia, L., Zhao, YQ. Constituents of ginseng and quality evaluation of ginseng products.  Drug evaluation research 2011; 34(3),1-5.

79.      Song M., Zhang, S., Xu, X., Hang, T., Jia, L. Simultaneous determination of three Panax notoginseng saponins by LC-MS/MS at sub-nanograms in dog plasma for pharmacokinetics of compound Danshen Tablets. J. Chromatogr. 878: 3331-7, 2010.

80.      Rayburn, E., Wang, W., Li, M., Zhang, X., Xu, H., Li, H., Qin, JJ., Jia, L., Covey, J., Lee, M., Zhang, R. Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemother. Pharmacol. 69:1423-31; 2012.

81.      Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, JM., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A.J., Kinders, R., Wang, L., Parchment, R.E., Carter, J., Stotler, H., Rubinstein, L., Hollingshead, M., Melillo, G., Pommier, Y., Bonner, W., Tomaszewski, JE., Doroshow, JH. Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Cancer Res. 71:5626-34; 2011.

82.      Meng, J., Yang, X.D., Jia.L., Liang, X.J., Wang, C. Impact of nanoparticles on cardiovascular diseases: modulating metabolism and function of endothelial cells. Curr. Drug Metab. 13: 1123-29; 2012. IF5.113

83.      Jia, X., Jia, L*. Nanomaterials improve biological functions of photosensitizers used for photodynamic therapy. Curr. Drug Metab. 13: 1119-22, 2012. IF5.113

84.      Xue, X., You, S., Zhang, Q., Wu, Y., Zou, GZ., Wang, PC., Zhao, YL., Xu, Y., Jia, L.,  Zhang, X., Liang, XJ. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction. Mol. Pharmaceutics 9:634−644 ;2012. IF4.782

85.      Shao, J., Xue, JP., Dai, YC., Liu, H, Jia*, L, Chen, NS., Huang, JL. Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitizer Photocyin: ROS production, apoptosis, and cell cycle arrest. Eur. J. Cancer. 48: 2086-96; 2012. ISSN:0959-8049; IF5.536

86.      Meng, J., Xing, J., Wang, Y., Lu, Y., Zhao, YL., Gao, X., Wang, P.C., Jia, L. Liang, XJ. Epigenetic modulation of human breast cancer by metallofullerene nanoparticles: in vitro analysis and in vivo treatment. Nanoscale. 3: 4713-19; 2011. IF5.914

87.      Zhang, F., Xie, JP., Shao, JW., Jia*, L. Compilation of 222 Drugs’ Plasma Protein Binding Data and Guidance for Study Designs. Drug Discovery Today 17:475-495, 2012. IF6.828

88.      Xu, Y., Jia, L. Nanoscaled Proteomic Analysis. 64-81, Chapter 4th In Nanopharmaceuticals Ed by Liang. World Scientific Publishing, Singapore. 2012.

89.      Jia, L.* Lu, Y., Shao, J., Liang, XJ., Xu Y. Nanoproteomics: a new spin from emerging links between nanotechnology and proteomics. Trends Biotech. 31:99-107, 2013. 一区 IF11.96

90.      Shao, JW., Dai, Y., Zou, WT., Xue, JP., Ye, J., Jia*, L. Intracellular distribution and mechanisms of actions of photosensitizer Zinc (II)-phthalocyanine solubilized in Cremophor EL against human hepatocellular carcinoma HepG2 cells. Cancer Lett. 330:49-56,2013. 二区 IF5.621

91.      Xie, JJ., Shao, JW., Lu, Y., Chen, JZ., Wang, J., Yu SH., Jia, L*. Separation of ginseng active ingredients and their roles in cancer metastasis supplementary therapy. Curr. Drug Metabo. 14:614-621;2013. 二区 IF4.8

92.      Jiang, Z., Shao, J., Chen, M, Hu, Y., Wang, J., Jia*,L. A novel SPE-HPLC method for simultaneous determination of selected sulfonated phthalocyanine zinc complexes in mouse plasma following cassette dosing. Analyst 138: 4385 – 4392, 2013. 二区IF4.2

93.      Jia*, L. Science Requires Coexisting of Opposite Opinions: “One Country, Two Systems” Pharmaceutical Reg. Affairs: Open Access ISSN:2167-7689; 1(4):1000e114;2012

94.      Shao, J., Jia*, L. Potential serious interactions between nutraceutical ginseng and warfarin in patients with ischemic stroke. Trends Pharmacol. Sci. 34(2):85-86, 2013. 一区IF11.54

95.      Yin, J.J., Sharma, S., Shumyak, S.P., Wang, Z.X., Zhou, Z., Zhang, Y., Guo, P., Li, C.Z., Kanwar, J.R., Yang, T.X., Mohapatra, S.S., Liu, W., Duan, W., Wang, J., Li, Q., Zhang, X., Tan, J., Jia, L. Liang, J., Wei, M.Q., Li, X., Zhou, S.F. Synthesis and Biological Evaluation of a Novel Cancer Treatment Based on Folic Acid Receptor-Targeted, β-Cyclodextrin-Based Drug Complexes for Cancer Treatment. PLoS ONE 8(5): e62289; 2013. 二区 IF4.8

96.      Gao, Y. Xie, J., Chen, H., Gu, S., Zhao, R., Shao, J., Jia*, L. Nanotechnology-based intelligent drug design for cancer metastasis treatment. Biotech Adv. 32:761-777, 2014. 一区 IF9.6

97.      Jiang, Z., Shao, J., Ting, Y., Wang, J., Jia*, L. Pharmaceutical development, composition and quantitative analysis of phthalocyanine as the photosensitizer for cancer photodynamic therapy. J. Pharm. Biomed. Anal. 78:98-104; 2014. 三区 IF 2.829
98.      Gao, Y., Shao, J., Jiang, Z., Chen, J., Gu, S., Yu, S., Zheng, K., Jia,*L. Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Disc. Today  19:326-340,2014. 一区 IF6.89

99.      Wang, J., Jiang, Z., Shao*, J., Ou, M., Li, Y., Lu, Y., Xiang, L., Lin, L., Dai, Y., Jia, L*, Synergism of ursolic acid derivative with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual targeting of apoptosis and glycolysis. Sci. Reports 2014, 4:5006; DOI: 10.1038/srep05006 二区 IF5.578

100.    Chen, JZ., Wang, JC., Shao, JW., Gao, Y., Xu, JG, Yu, SH., Liu, ZH., Jia, L*. The Unique Pharmacological Characteristics of Mifepristone: from Terminating Pregnancy to Preventing Cancer Metastasis. Med. Res. Rev. 34:979–1000, 2014. 一区 IF 9.583

101.    Wang, J., Chen, J., Wan, L., Shao*, JW., Lu, Y., Zhu, Y., Ou, M., Yu, SH., Chen, HJ., Jia*, L. Synthesis, spectral characterization and pharmacological evaluation of metapristone, a novel cancer metastatic chemopreventive derived from mifepristone (RU486). AAPS J. 16:289-298, 2014. 二区 IF 4.905

102.    Reid, JM., Buhrow, SA., Gilbert, JA., Jia, L., Shoji, M., Snyder, J., Ames. MM. Mouse pharmacokinetics and metabolism of the curcumin analog, 4-Piperidione,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993) Cancer Chemother. Pharmacol. 73(6):1137-46, 2014.  IF3

103.    Chen, JZ., Wang, JC., Gao, Y., Zeng, R., Jiang, Z., Zhu, YW., Shao, JW., Jia*,L. A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486). J Pharm. Biomed. Anal, 95:158-63; 2014 三区 IF 2.829     

104.    Lu, Y., Yu, T., Liang, H., Wang, J., Xie, J., Shao*, J., Gao, Y., Yu, S., Chen, S., Wang, L., Jia,*L. Nitric oxide inhibits hetero-adhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initial metastatic cascade.  Scientific reports 2014; 4:4344. DOI: 10.1038/srep04344,2014二区 IF5.578

105.    Chen, P., Zhang, X., Jia, L., Prud'homme, RK., Szekely, Z., Sinko, PJ. Optimal structural design of mannosylated nanocarriers for macrophage targeting. J. Controlled Release 2014; 194:341-34. IF7.705

106.    XIE, JJ., ZHAO R., CHEN, HN., XIE, XD., JIA,* L. Specificity of Capturing and Restraining Colon Cancer Cells in Vitro by Multifunctional Nanomaterial Conjugates 科技导报2014, 32(34):26-32. doi 10.3981/j.issn.1000-7857.2014.34.002

107.    Xie, JJ, Zhao, R, Gu, S., Dong, H., Wang, J., Lu, Y., Sinko, PJ., Yu, T., Xie, FW., Wang, L., Shao*, J., Jia, L* The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their hetero-adhesion to endothelial cells for metastasis prevention. Theranostics 2014;4: 1250-63; 二区IF8.022

108.    Xie, JJ., Lu, Y., Dong, HY., Zhao, RL., Chen, HN., Shen, WY., Sinko, PJ., Zhu, Y., Wang, JC., Shao, JW., Gao, Y., Xie, FW., Jia*, L. Enhanced specificity in capturing and restraining circulating tumour cells with dual antibody-dendrimer conjugates. Adv. Funct. Mater. 2015, 25, 1304–1313一区 IF11.805.

109.    Yu, S., Yang, XT., Zhu, Y., Xie, FW., Lu, YS., Yu, T., Yan, CC., Shao, J., Gao, Y., Mo, F., Cai, GN., Sinko, PJ., Jia, L.* Systems biological pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex. Sci. Rep., 5: 7830, 2015 二区 IF5.578

110.     Xie, J., Dong, HY., Chen, HN., Zhao, R., Sinko, JP., Shen, WY., Wang, JC., Lu, YS., Yang, XT., Xie, FW., Jia,* L. Exploring cancer metastasis prevention strategy: interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial J. Nanobiotechnology, 2015; 13:9. DOI 10.1186/s12951-015-0072-x  一区 IF6.015

111.     Xie J, Wang, J., Chen H, Shen, WY., Sinko JP., Dong H., Zhao R., Lu Y., Zhu YW., Jia L*. Multivalent Conjugation of Antibody to Dendrimers for the Enhanced Capture and Regulation on Colon Cancer Cells. Sci. Reports 5: 9445, 2015;二区 IF5.578

112.    Dong, HY., Yang, X., Xiang,L., Li, YF., Ou, M., Chi, T., Liu, ZH., Shao*, JW., Jia*, L. UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma. Biochem. Pharmacol. 2015; 93:151-162二区 IF 5.009.

113.    Xu, J., Dong, H., Shen, W., He, S., Li, H., Lu, Y., Wu, Z.-S*., Jia, L*., New molecular beacon for p53 gene point mutation and significant potential in serving as the polymerization primer. Biosensors Bioelectronics 2015; 66:504-511. IF 6.451.

114.    Jiang, Z., Yang, J., Pang, YQ., Yang, XT., Yu*, SH., Jia*, L. Bioactivity-guided fast screen and identification of cancer metastasis chemopreventive components from raw extracts of Murraya exotica J. Pharm. Biomed. Anal. 107C:341-45, 2015. 三区 IF 2.98

115.    Gao*, Y., Li, ZR., Xie, XD., Wang, CQ.,You, J., Mo, F., Jin, B., Chen, JZ., Shao, JW., Chen, HJ., Jia*, L. Dendrimeric anticancer prodrugs for targeted delivery of ursolic acid to folate receptor-expressing cancer cells: synthesis and biological evaluation. Eur. J. Pharm. Sci. 70:55-63, 2015. IF3.01.

116.    Lu, Y., Liang, HY., Yu, T., Xie, JJ., Chen, SM., Dong, HY., Sinko, PJ., Lian, S., Xu, JG., Wang, JC., Yu, SH., Shao, JW., Yuan, B., Wang, L., Jia,* L. Isolation and Characterization of Alive Circulating Tumor Cells by Immunomagnetic Negative Enrichment Coupled with Flow Cytometry. Cancer 121(17):3036-45, 2015. IF4.901.

117.    Wan#, LY, Dong#, HY, Xu, H., Zhu, YW., Lu, Y., Ma, J., Wang, JC., Xie, JJ., Xu, B., Gao, Y., Shao, JW., Jia, L* Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil. Oncotarget. priority publication; 6(34):35157-72;2015. IF6.63.

118.     R.J. Zeng, Y. Li, J.Z. Chen*, G. X. Chou*, Y. Gao, J.W. Shao, L. Jia, and S.S. Wu, A novel UPLC-MS/MS method for sensitive quantitation of boldine in plasma, a potential anti-inflammatory agent: application to a pharmacokinetic study in rats. Biomed. Chromatogr. 29:459–464, 2015. (IF=1.95)

119.     Xiang, LP., Chi, T., Tang, Q., Yang, X., Ou, M., Chen, X., Yu, XB., Chen, JZ., Shao*, JW.,  Jia, L.  A pentacyclic triterpene natural product, ursolic acid and its prodrug US597 inhibit targets within cell adhesion pathway and prevent cancer metastasis. Oncotarget  2015, 6(11):9295-312. IF6.63.

120.     Xie, J., Yu, G., Zhao, R., Sinko, P., Gu, S., Wang, J., Li, Y., Lu, Y., Yu, S., W, Lie., Chen, S., Shao, J., Jia,* L. Ex vivo and in vivo capture and deactivation of circulating tumor cells by dual-antibody-coated dendrimers. J. Control Release. 2015; 209:159-69.一区IF7.705.

121.     Dong, HY., Wu* ZS, Xu, JG., Ma, J., Zhang, HJ., Wang, J., Shen, WY., Xie, JJ., Jia,*L Novel multifunction-integrated molecular beacon for the amplification detection of DNA hybridization based on primer/template-free isothermal polymerization. Biosensors Bioelectronics 72:182-190, 2015. IF6.45

122.     Xu JG., Wu* ZS., Shen, WY., Xu, H, Li, LH., Jia,* L. Cascade DNA nanomachine and exponential amplification biosensing. Biosensors and Bioelectronics. 73:19-25, 2015. IF 6.451.

123.     Gao§,Y., Gu§, S., Zhang, Y., Xie, XD., Yu, T., Lu, Y., Zhu, Y., Chen, WG., Zhang, H., Dong, HY., Sinko, PJ., Jia,* L. The architecture and function of monoclonal antibody-functionalized mesoporous silica nanoparticles loaded with mifepristone: repurposing abortifacient for cancer metastatic chemoprevention. Small. 2016;12(19):2595-608   IF8.368.

124.     Dong, HY#, Gao, Y#, Sinko, PJ., Wu, ZS., Xu, JG., Jia,*L. The nanotechnology race         between China and the United States. Nano Today. 11:7-12; 2016. IF18

125.     Gao Y., Jin B., Shen WY., Sinko PJ., Xie XD., Zhang, HJ., Jia* L. China and the United States- global partners, competitors and collaborators in nanotechnology development. Nanomedicine: Nanotechnology, Biology, and Medicine. 12:13-19;2015. IF6.5  doi: 10.1016/j.nano.2015.09.007.

126.     Li, Y., Zeng, RJ., Chen*, JZ., Wu, BY., Chou,*GX., Gao, Y., Shao, JW., Cai, HZ., Jia, L. Pharmacokinetics and metabolism study of isoboldine, a major bioactive component from Radix Linderae in male rats by UPLC-MS/MS. J. Ethnopharmacol. 2015, 171:154-60. IF3

127.     Xu, JG., Qian, J., Li, H., Wu,* ZS., Shen, W., Jia,*L.  Intelligent DNA machine for the ultrasensitive colorimetric detection of nucleic acids. Biosensors and Bioelectronics, 2016,75:41-47. IF6.45

128.     Xiao#, YY., Zhu#, YW., Yu#, SH., Ho, RJ., Yan, CC., Liu, J., L, T., Wang, J., Wan, LY., Yang, XT., Xu, H., Wang, JC., Jia,* L. Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone. Toxicol. Mech. & Methods 2016; 6: 36-45. IF2

129.     Xu, JG., Li, HN., Wu ZS*., Qian, J., Xue, C. Jia* L. Double-stem Hairpin Probe and Ultrasensitive Colorimetric Detection of Cancer-related Nucleic Acids. 2016; 6(3): 318-327. Theranostics. IF8.85

130.     Xie, XD., Li, FQ., Zhang, HJ., Lu, YS., Lian, S., Lin, H., Gao*, Y., Jia* L. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Eur. J. Pharm. Sci. 2016; 83:28-35. IF3.35二区

131.     Dong, HY., Ma, J. Wang, J., Wu,* ZS., Sinko, PJ.,  Jia*, L. A biofunctional molecular      beacon for detecting single base mutations in cancer cells. Mol Ther Nucleic Acids. 2016 Apr 5;5:e302. doi: 10.1038/mtna.2016.18; IF6.4. 二区

132.     Jiang#, Z., Pang# Y, Yu#, XB., Zhou, SX., Qian, J., Zheng, N., Dong, HY., Shi, Q., Jia* L. The paradigm-shifting idea and its practice: from traditional abortion Chinese medicine Murraya paniculata to safe and effective cancer metastatic chemopreventives.  Oncotarget 2016; 7(16): 21699-712. Mar 5.  IF5.2

133.     Yu,#SH*, Yan#, CC, Yang#, XT., He, SD., Liu, J., Qin, CT., Huang, CZ., Lu, YS., Tian, ZQ., Jia,* L. Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin for cancer metastasis chemoprevention. Sci. Rep. 6, 22388; 2016. doi:10.1038/srep22388. IF5.578

134.      Wang, JC.#, Chen, JZ.#, Zhu, YW., Zheng, N., Liu, J., Xiao, YY., Lu, YS., Dong, HY.,   Xie,JJ., Shao, JW., Yu, SH., Jia,*L. In vitro and in vivo efficacy and safety evaluation of      metapristone and mifepristone as cancer metastatic chemopreventive agents. Biomed        Pharmacother. 78 (2016) 291–300. IF2 

135.      Dong HY.#, Wang#, J., Zhang, T., Ma, J., Han, LY., Tu, XH., Jia*L. Aptamers and their       biological applications to bio-medicine and analytical diagnostics. Chin J Pharm Anal 2016; 36(3):369-376.

136.      Xu, JG., Wu*, ZS., Wang, ZM., Li, HN., Le, JQ.,  Jia* L. Two-wheel drive-based DNA   nanomachine and its sensing potential for highly sensitive analysis of cancer-related gene. Biomaterials. 2016; 100:110-117. IF8.557

137.      Xu, JG., Wu, *ZS., Li, HN., Wang, ZM., Le, JQ., Zheng, TT., Jia,*L. Dual-cyclical nucleic      acid strand-displacement polymerization based signal amplification system for highly   sensitive determination of p53 gene.  Biosensors and Bioelectronics 2016, 86: 1024–30    IF7.7

138.      Li, HN. Xu, JG., Wang ZM., Wu, # ZS., Jia, *L. Increasingly branched rolling circle      amplification for the cancer gene detection. Biosensors and Bioelectronics. 2016; 86:       1067-73. IF7.7

139.      Shao, JW., Zhou, SX., Jiang Z., Chi, T., Ma, J., Guo, ML., Lee, A., Jia,*L Warfarin and    coumarin-like Murraya paniculata extract down-regulate EpCAM-mediated cell adhesion:       individual components versus mixture for studying botanical metastatic chemopreventives
Scientific Report 2016, 6:30549 | DOI: 10.1038/srep30549.
140.      Lian, S., Lu., YS., Cheng YL., Yu, T., Xie, XD., Liang, HY., Jia, *L. S-nitrosocaptopril      interrupts cancer cell adhesion to endothelium by suppressing cell adhesion molecules   via inhibition of the NF-кB signal pathway in endothelial cells. Eur J Pharmacol. 2016;      791:62-71. IF2.53.
141.      He, S., Yang, T., Yan, CC., Jiang* Z., Yu, SH., Zhou, SY., Jia*,L. Promising Compounds      from Murraya Exotica for Cancer Metastasis Chemoprevention. Integr. Cancer Ther. 2017;16:556-562. doi: 10.1177/1534735416678981 IF1.7
142.      Tang, Q., Liu, YJ., Li, T., Yang, X., Zheng, GR., Chen, HN., Jia, L., Shao* JW. A novel co-drug of aspirin and ursolic acid interrupts adhesion, invasion and migration of cancer cells to vascular endothelium via regulating EMT and EGFR-mediated signaling pathways: multiple targets for cancer metastasis prevention and treatment. Oncotarget. 2016; 7(45):73114-73129.
143.      Xu, JG., Wu* ZS, Chen, YR., Zheng, TT., Le, JQ., Jia* L. Collapse of chain anadiplosis-    structured DNA nanowires for highly sensitive colorimetric assay of nucleic acids.  Analyst. 2017,142, 613-620  二区
144.       Zhang, H., Wu, FQ., Li, YZ., Yang, XP., Huang, JM., Lu, TT., Zhang, YY., Chen*, JZ.,   Chen, HJ., Gao*, Y., Liu, G., Jia, L. Chitosan-based nanoparticles for improved anticancer efficacy and bioavailability of mifepristone. Beilstein J. Nanotech. 2016,     7:1861-1870. IF2.778; 二区
145.       Dong, HY., Ma, J., Li, T., Xiao, YY., Zheng, N., Liu, J., Gao, Y., Shao, JW., Jia* L Global deregulation of ginseng products may be a safety hazard to warfarin takers: solid evidence of ginseng-warfarin interaction  Sci. Rep. 2017 Jul 19; 7(1):5813. doi: 10.1038/s41598-017-05825-9 IF4.1
146.       Jiang, Z#, Qian, J#, Dong, H#, Yang, J., Yu, X., Chen, JZ., Chen, HN., Shi, Q., Jia*, L. The traditional Chinese medicine Achyranthes bidentata and our de novo conception of its metastatic chemoprevention: from phytochemistry to pharmacology. Sci Rep. 2017, 7(1):3888. doi: 10.1038/s41598-017-02054-y  IF4.1
147.       Xu, J., Wu,*ZS., Wang, ZM., Le, JQ., Zheng, TT., Jia,*L. Autonomous assembly of ordered metastable DNA nanoarchitecture and in situ visualizing of intracellular microRNAs. Biomaterials. 2017; 120:57-65. IF8.5
148.       Chen, WG., Xiao, YY., Chen, JZ., Liu, J., Shao, JW., Li, T., Zhu, YW., Ma, J. Gao, Y., Wang JC., Xu, JG., Lu, YS., Yu, SH., Jia* L. Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite). Sci. Reports  2017; 7(1):17190. doi: 10.1038/s41598-017-17225-0. IF5
149.       Xu, H., Xue, C., Zhang, RB., Chen, YR., Li, F., Jia, L., Wu, ZS. Exponential rolling circle    amplification and its sensing application for highly sensitive DNA detection of tumor   suppressor gene. Sensors and Actuators B 2017; 243: 1240–1247  IF5.401一区,Top期刊
150.       Xu H., Wu, D., Zhang YF., Shi, H., Ouyang, C., Li, F., Jia, L., Yu, SH., Wu*, ZS. RCA-enhanced multifunctional molecule beacon-based strand-displacement amplification for sensitive microRNA detection  Sensors & Actuators: B 2018; 258: 470-77. IF5.401一区,Top期刊
151.        Wu, J., Yu, X., Liu, J., Lin, Y., Gao, Y., Jia, L., Chen* HJ. Synthesis of metapristone       through an efficient N-demethylation of mifepristone. RSC Adv., 2016; 6, 7195-7197
152.        Li, FQ, Mei, H, Xie, XD., Zhang, HJ., Liu,J., Lv, TT., Nie, HF., Gao*, Y., Jia,*L. Aptamer-    Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib     to EGFR-Mutated Lung Cancer Cells. AAPS J., 19(3):814-826, 2017.  IF4.385
153.        Dong, HY., Han, L., Wu, ZS., Zhang, T., Xie, JJ., Ma, J., Wang, J. Li, T., Gao, Y., Shao, JW., Sinko, P., Jia*,L Biostable aptamer rings conjugated to target two biomarkers on circulating tumor cells in vivo with great precision.  Chem. Mater. 2017, 29:10312–10325. IF9.890 一区
154.        Xu, J, Wu, ZS.*, Shen, WY., Le, JQ., Zheng, TT., Li, H., Jia,*L. Programmable nanoassembly consisting of two hairpin-DNAs for p53 gene determination. Biosensors and Bioelectronics. 2017; 94: 626–631. IF8.173 一区
155.        Gao, Y., Xie, XD., Li, FQ., Lu, YS., Li, T., Lian, S., Zhang, YY., Zhang, H., Mei, H., Jia*L The novel nanomissile targeting two biomarkers and accurately bombing CTCs with doxorubicin. Nanoscale 2017; 9:5624-5640 一区 IF7.367
156.        Zheng N., Chen, JH., Liu, WQ., Wang, JC., Liu, J., Jia,*L. Metapristone (RU486 derivative) inhibits cell proliferation and migration as melanoma metastatic chemopreventive agent. Biomed. & Pharmacother. 90 (2017) 339–349
157.        Zheng N, Chen J, Li T, Liu W, Liu J, Chen H, Wang J, Jia*L. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention. Mol Carcinog. 2017 56(8):1896-1908. IF3.851二区
158.        Zheng, N., Chen, JH., Liu, WQ., Wang, JC., Liu, J., Jia,*L Ovarian Cancer Cell Metastasis Is Inhibited by Mifepristone through Intervening in the SDF-1/CXCR4 Chemokine Axis. Oncotarget 2017; 8(35):59123-59135 IF5.168
159.        Jiang, K., Chi, T., Li, T., Zheng, G., Fan, L., Liu, YJ., Chen, XF., Chen, XJ., Jia, L., Shao*, JW., A smart pH-responsive nano-carrier as a drug delivery system for targeted delivery of ursolic acid: suppresses cancer growth and metastasis by modulating P53/MMP-9/PTEN/CD44 mediated multiple signaling pathways. Nanoscale 2017; 9(27):9428-9439. IF7.367
160.        Zheng#, GR., Shen#, ZC., Chen, HN., Liu, J., Jiang, K., Fan, L., Jia, L., Shao*JW. Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway. Biomedicine & Pharmacotherapy 90 (2017) 437–445 IF3.46
161.        Shao#, JW., Zheng#, GR., Chen, HN., Liu, J., Li, T. Lu, Y., Xu, JG., Zheng, N., Jia*L. Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway. Oncotarget. 2017; 8(45): 78351-78364 IF5.168
162.        Xu, H., Wan, L., Xu, JG., Liu, J., Zheng, N., Wu, ZS., Jia,*L HAMPT, a novel quadruple     drug combination designed for cancer metastatic chemoprevention: from hypothesis to      proof-of-concept. Curr. Cancer Drug Target (in press), 2018
163.        Xu, JG., Zheng, TT., Le, JQ., Jia*,L Long-stem shaped multifunctional molecular beacon for highly sensitive nucleic acids determination via intramolecular and intermolecular interactions based strand displacement amplification  Analyst, 2017, 142, 4438-45. IF3.864 二区
164.        Li, FQ., Mei, H., Gao*,Y., Xie, XD., Nie, HF., Li, T., Zhang, HJ., Jia*L. Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer. Biomaterials. 2017;145:56-71. IF8.5一区
166.        Shi, Q,Jiang,Z., Yang,JY., Cheng,YL., Pang,YQ., Zheng,N., Chen,JH.,  Chen,WG., Jia*L. A Flavonoid Glycoside Compound from Murraya paniculata (L.) Interrupts Metastatic Characteristics of A549 Cells by Regulating STAT3/NF-κB/COX-2 and EGFR Signaling Pathways. AAPS J. 2017; 19(6):1779-1790 IF4.4 二区
167.        Xu, JG., Zheng, TT., Le, JQ., Jia,*L. Stepwise nanoassembly of a single hairpin probe and its Biosensing. Talanta  187 (2018) 272–278.  IF4.244 二区
168.        Chen, WG., Xiao, YY., Cheng, YL., Chen JZ., Chen, JH., Jiang K., Zhou YY., Jia,*L Pharmacokinetic differences of mifepristone between sexes in animals. J Pharm Biomed. Anal. 2018; 154, 108–115.       IF3.255 二区
169.         Dong, HY, Han, LY., Wang, J., Xie, JJ., Gao, Y., Xie, FW, Jia,*L, In vivo inhibition of circulating tumor cells by two apoptosis-promoting circular aptamers with enhanced specificity. J. Control Release 2018; 280: 99-112. IF7.87 一区
170.         Wang, J., Dong, HY., Han, LY., Zhang, T., Lin, M., Wang, JH., Xu, H., Wu, ZS., Jia*L. Immunomagnetic antibody plus aptamer pseudo-DNA nanocatenane followed by rolling circle amplication for highly-sensitive CTC detection. Biosensors & Bioelectronics. 2018; 122: 239-46. IF8.173 一区 doi:10.1016/j.bios.2018.09.025
171.         Wang J, Dong H, Liu J, Zheng N, Xie X, Jia*L.The evaluation of animal models in the development of anticancer agents : from preclinical to clinical tests. Curr Cancer Drug Targets. Curr Cancer Drug Targets. 2019;19(4):277-284. IF2.626 医学2区
172.         Zheng, TT., Gao, Y., Deng, XX., Liu, HB., Liu, J., Liu, R., Li, YL., Jia*L Differences and similarities between graphene oxide and graphdiyne oxide in physicochemistry biology and cytotoxicity. ACS Appl Mater Interfaces. 2018;10(39):32946-32954  SCI一区Top, IF8.097. DOI: 10.1021/acsami.8b06804. (ACS Editors’ choice article)
173.         Xie X, Zhang Y, Li F, Lv T, Li Z, Chen H, Jia*L, Gao*Y. Challenges and opportunities from basic cancer biology for nanomedicine for targeted drug delivery. Curr. Cancer Drug Targets. 2018. DOI : 10.2174/1568009618666180628160211 IF2.626 医学2区
174.         Gao, Y., Zhang, HJ, Zhang, YY, Lv, TT, Zhang, L., Li, ZY, Xie, XD., Li, FQ., Chen, HJ., Jia,*L Erlotinib-Guided Self-Assembled Trifunctional Click Nanotheranostics for Distinguishing Druggable Mutations and Synergistic Therapy of Nonsmall Cell Lung Cancer  Mol. Pharmaceutics. 2018; 15, 5146−61. IF4.6 二区
174.         Cheng, YL, Lu, YS, Zhang, DD., Lian, S., Liang, HY, Ye, YY., Xie, RZ., Li, SH., Chen, Jh., Xue,  Xie, JJ., Jia,*L Metastatic cancer cells compensate for low energy supplies in hostile microenvironments with bioenergetic adaptation and metabolic reprogramming. International J. Oncology 2018; 53:2590-2604. IF2.69
175.          Zhou, YY., Lin, M., Wang, J., Chen, F., Li, FY., Chen, WG., Han, LY., Wang, CH., Chen, JM., Shao, JW., Jia,*L. A Novel S-Nitrosocaptopril Monohydrate for Pulmonary Arterial Hypertension: H2O and –SNO Intermolecular Stabilization Chemistry. Free Radical Biology and Medicine 2018;129: 107-15.二区, IF6.02
176.          Li C, Lin J, Wu P, Zhao R, Zou J, Zhou M, Jia L, Shao J. Small Molecule Nanodrug Assembled of Dual-Anticancer Drug Conjugate for Synergetic Cancer Metastasis Therapy. Bioconjug. Chem. 2018; 29(10):3495-3502. IF4.48
177.          Jiang, Z., Ye, J., Yang, J., Wang,*J., Jia,*L., Ho, RJY. Conjugation of phthalocyanine photosensitizer with poly(amidoamine) dendrimer: improved solubility, disaggregation and photoactivity against HepG2 cells. Curr Cancer Drug Targets. 2019;19(4):312-320
178.          Zheng, N., Liu, WQ, Chen, JH, Li, BF., Liu, J., Shi, Q., Wang, JC., Gao, Yu., Shao, JW., Jia,*L. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer. Mol Carcinog. 2019; 58(1):144-155
179.          He, S., Yang, X., Yan, CC., Chen, WG., Lu, Y., Zhou Y., Liu, J., Jia*, L. S-nitrosylation of cyr61 protein reduced triple-negative breast cancer metastasis ability. (under revision) 2018
180.          Le, JQ., Xu, JG., Zheng, JX., Li, BF., Zheng, TT., Lu, YS., Shen, WY., Kudryavtseva, AV., Katanaev, VL., Shao, JW., Jia*L. One nanometer self-assembled aptamer-DNA dendrimers carry 350 doxorubicin: super-stability and intra-nuclear DNA comet tail. Theranostics (revision submitted) 2019.
181.          Xie, XD., Nie, HF., Zhou, Y., Lian, S., Mei, H., Li, F., Li, T., Li, BF., Wang, J., Lin, M., Wang, CH., Zhang, XQ., Shao, JW., Gao, Y., Chen, JM., Xie, FW., Jia,*L Eliminate blood oncogenic exosomes into small intestine. NCOMM. (IF12) Submitted 2019
182.          Wang, J. Yu, XB, Shao, JW., Liu, J., Dong, HY., Yu, T., Liang, HY, Shi, Q., Jia,*L. Embedding similarities between blastocyst and cancer cells: fundamentals for abortifacients used for cancer metastatic chemoprevention. Cancer (submitted) 2019
183.          Lu Y, Lian S, Ye Y, Yu T, Liang H, Cheng Y, Xie J, Zhu Y, Xie X, Yu S, Gao Y, Jia* L. S-nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells. Pharmacol. Research, 139 (2019) 535–549 IF5
184.          Lian S#, Lu YS#, Cheng YL, Xie RZ, Li SH, Yu T, Liang HY, Jia*L S-nitrosocaptopril inhibits hetero-adhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initiating metastatic cascade. doi: 10.16155/j.0254-1793. 2019  pharmaceutical analysis
185.          谢瑞芝,黎必非,练殊,李书慧,贾力# “表面蛋白EpCAM用于检测循环肿瘤细胞缺陷的研究进展” 《癌症进展》2018年10月第16卷第10期。
186.          Chao Li, Juanfang Lin, Pengyu Wu, Ruirui Zhao, Junjie Zou, Min Zhou, Jia, L. Jingwei Shao*. Small Molecule Nanodrug Assembled of Dual-Anticancer Drug Conjugate for Synergetic Cancer Metastasis Therapy. Bioconjugate Chem. 2018, 29,3495-3502
187.          Liu, J. Zhang, D., Lian, S., Zheng, JX., Li, BF., Li, T., Jia*L. Redox-responsive hyaluronic acid-functionalized graphene oxide nanosheets for targeted delivery of water-insoluble cancer drugs  Int. J. Nanomedicine 2018; 13: 7457–7472 (IF 4.37, 二区)
188.          Liu, J. Zheng, JX., Zhang, DD., Cao, DR., Xing, Z., Li, BF., Jia,*L. Molybdenum disulfide-based hyaluronic acid-guided multifunctional theranostic  nanoplatform for magnetic resonance imaging and synergetic chemo-photothermal therapy J. Colloid and Interface Science (IF 5.09, 二区,accepted).
189.         Weiyu Shen, Yumei Li, Bifei Li, Yusheng Lu, Jie Wang, Chen Zhang, Huo Xu, Tao Li, Fan Chen, Liping Zheng4, Lee Jia. The core survival proteomics responsible for melanoma metastasis. Cell Research 2019 (submitted)
190.         Weiyu Shen#, Bifei Li#, Yumei Li, Liping Zheng, Xiaodong Xie, Jingqing Le, Yusheng Lu, Tao Li, Fan Chen, Lee Jia* Downregulation of KCTD12 contributes to melanoma stemness by modulating CD271   Cancer Biol. Med. (IF4.6; 2区)已经接收
191.          Lu Y, Lian S, Cheng Y, Ye Y, Xie X, Fu C, Zhang C, Zhu Y, Iqbal Parker M, Jia*L. Circulation patterns and seed-soil compatibility factors cooperate to cause cancer organ-specific metastasis. Exp Cell Res. 2019; 375(1):62-72. 
192.          Lian, S., Xie, RZ., Ye, YY., Xie, XD., Li, SH., Lu, YS., Li, BF., Cheng, YL. Katanaev, VL., Jia,*L  Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. EBioMedicine 42 (2019) 281–295 IF6.183; 医学1区
193.          Lian, S., Xie, RZ., Ye, YY., Lu, YS., Cheng, YL., Xie, XD., Li, SH., Jia,*L. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. Sci. Rep. 2019, 9:4532  doi.org/10.1038/s41598-019-40241-1.
194.          Chen Zhang#, Doudou Zhang#, Jian Liu#, Yusheng Lu, Junxia Zheng, Bifei Li, Lee Jia, Functionalized MoS2-erlotinib produces hyperthermia under NIR (under revision)
195.          Jian Liu, Junxia Zheng, Bifei Li, Doudou Zhang, Lee Jia*,Redox/near-infrared light dual-responsive hyaluronic acid-functionalized MoS2 nanosheets for controlled drug release and synergetic chemo-photothermal therapy. ACS biomaterials science & engineering (IF 4.43, 二区,under review).
196.          Xie R, Lian S, Peng H, OuYang C, Li S, Lu Y, Cao X, Zhang C, Xu J, Jia*L. Mitochondria and nuclei dual-targeted graphitic hollow carbon nitride nanospheres for cancer chemo-photodynamic synergistic therapy. Mol Pharm. 2019 Apr 2. IF 4.556  doi: 10.1021/acs.molpharmaceut.9b00259. 
197.          Xu H, Wan L, Xu J, Liu J, Zheng N, Jia*L. HAMPT, A Novel Quadruple Drug Combination Designed for Cancer Metastatic Chemoprevention: From Hypothesis to Proof-of-concept.
Curr Cancer Drug Targets. 2019;19 (4):296-303.
198.          Shen, WY., Li, YM., Li, BF., Zheng, LP., Xie, XD., Le, JQ., Lu, YS., Li, T., Chen F., Jia*L. Downregulation of KCTD12 contributes to melanoma stemness by modulating CD271 2019; Cancer Biology & Medicine. (in press) IF4.6
199.          Li, BF., Shen, WY., Peng, HY., Li, YM., Chen, F., Zheng, LP., Xu, JH., Jia*L., Fibronectin 1 promotes melanoma proliferation and metastasis by inhibiting apoptosis and regulating EMT.  OncoTargets Therapy 2019:12 3207–3221
200.          Zheng, N., Liu, WQ., Li, BF., Nie, HF., Liu, J., Cheng, YL., Wang, JC., Dong, HY., Jia,*L CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib. J. E CC  2019 (revised) 

© 2014 版权所有 福州大学肿瘤转移预警和预防研究所 地址:福州大学 访问量: